
Advanced Enzyme Q4 FY26 Results: Revenue Growth Outlook
Updated: 10 Mar 2026 • 1:32 pm
Posted by:

Advanced Enzyme Technologies Q4 FY26 results date is all set to be announced soon and most investors are awaiting it. Professionals are expecting an increase in revenue due to higher sales and a significant rise in PAT. Advanced Enzyme Technologies was listed on the National Stock Exchange (NSE) on 01-Aug-2016. Advanced Enzyme Technologies share has its face value of 2 per share, and its NSE symbol is ADVENZYMES. The company operates in the Healthcare sector and primarily belongs to the Biotechnology industry.
Advanced Enzyme Technologies Q4 Results 2026 Preview
- Advanced Enzyme Technologies Q4 FY26 revenue is expected to be around Moderate Growth Expected, representing a 9-12% YoY increase compared to the same quarter last year.
- Profit After Tax, or PAT, is projected to rise 10-14% YoY.
- EBITDA to rise 11%.
- Advanced Enzyme Technologies is expected to show Moderate Growth Expected in its revenue.
Click and Sign Up to Get Live Updates on Q4 Results
Advanced Enzyme Technologies Share Performance
- Over the past six months, Advanced Enzyme Technologies share price has 18% by 9-13% to 297.5.
- Moreover, over the past year, the stock has 30% by Up
- Despite this weak short-term performance, Advanced Enzyme Technologies stock has delivered a financially sound 140% return over the past 5 years.
- As of today, 10-03-2026, the Advanced Enzyme Technologies share price is trading at 297.5 per share.
Key Factors to Watch for Advanced Enzyme Technologies Q4 Results FY26
- Revenue Growth & Segment Performance – Focus on topline growth in the Biotechnology industry within the Healthcare sector.
- Occupancy Levels & Seat Expansion – Monitor operational expansion and capacity utilisation trends.
- Profitability & Margin Trends – Track EBITDA and PAT margins to evaluate cost control and operating efficiency.
- Order Book & New Client Wins – Watch for updates on new contracts, partnerships, and long-term deals.
- Balance Sheet & Cash Flow Position – Review debt levels, working capital management, and operating cash flows for financial stability.
About Advanced Enzyme Technologies
Advanced Enzyme Technologies is a biotechnology company focused on developing and manufacturing enzyme-based solutions for sectors including pharmaceuticals, food, animal nutrition, and textiles, serving global markets as a leading provider of specialty enzyme products.
Download the Univest iOS App or Univest Android App to get daily stock recommendations and insightful research pieces!
Final Thoughts
Advanced Enzyme Technologies is gear up to announce its Q4 FY26 results. Analysts expect 9-12% revenue growth, a 10-14% rise in PAT, and a 11% rise in EBITDA. Advanced Enzyme Technologies focuses on revenue growth from order execution, margin improvement, a strong order book, and management.
Stay informed with Univest blogs to get real-time updates on Advanced Enzyme Technologies Q4 results FY26.
Disclaimer: Investment in the share market is subject to risk. This news article is for informational purposes only. Conduct your own research before investing in shares and other securities.
Recent Articles
Adani Green Energy Q4 FY26 Results Preview: Renewable Energy Momentum
Adani Enterprises Q4 FY26 Earnings Preview: What to Expect
ACE Q4 FY26 Earnings Preview: Infra and Equipment Demand
Accelya Solutions Q4 FY26 Results Preview: Aviation Tech Demand
Abbott India Q4 FY26 Earnings Preview: Healthcare Growth Outlook
Recent Articles

Gold Price Today, 30 October 2026: MCX Gold Falls 1.25% to Rs 1,40,808 Per 10 Grams and Spot Gold Slips Below $4,000, a 3.5-Month Low, as December Fed Hike Bets Build Ahead of Dhanteras
30 October 2026

Anthropic IPO Valuation: Aswath Damodaran Values the Claude Maker at $1.475 Trillion, Just Below the Reported $1.5 to $2 Trillion IPO Range, With Scenarios From Negative $373 Billion to $4.04 Trillion
30 October 2026

Equitas Small Finance Bank Share Price Crashes 10% to Rs 51.25 on 30 October 2026, Down 21% in Two Days After CEO PN Vasudevan Resigns Despite Record Equitas Q2 Results: What Is Going On?
30 October 2026

Greaves Cotton Share Price Jumps 10% Despite 81% Fall in Q2 Profit: What Is Driving the Rally?
30 October 2026
Note: This blog is for information purpose only. Investments and trading are subject to market risks, read all scheme related documents carefully.
Reviews
Recent Posts
Gold Price Today, 30 October 2026: MCX Gold Falls 1.25% to Rs 1,40,808 Per 10 Grams and Spot Gold Slips Below $4,000, a 3.5-Month Low, as December Fed Hike Bets Build Ahead of Dhanteras
Anthropic IPO Valuation: Aswath Damodaran Values the Claude Maker at $1.475 Trillion, Just Below the Reported $1.5 to $2 Trillion IPO Range, With Scenarios From Negative $373 Billion to $4.04 Trillion
Equitas Small Finance Bank Share Price Crashes 10% to Rs 51.25 on 30 October 2026, Down 21% in Two Days After CEO PN Vasudevan Resigns Despite Record Equitas Q2 Results: What Is Going On?
Greaves Cotton Share Price Jumps 10% Despite 81% Fall in Q2 Profit: What Is Driving the Rally?
Asian Paints Share Price After Q2 Results: Profit Up 7%, but Price Hikes Are Yet to Brighten Margins
Popular this week
Borosil Share Price Jumps 16% After Strong Q2 Results: Record Profit, Margin Jump and Key Price Levels to Know

Uniresearch Global Pvt Ltd
Research Analyst
SEBI Registration Number — INH000013776
Uniresearch is a subsidiary of Univest Communication Technologies Private Limited
Company Address: Registered Address: Ground Floor, Unitech Commercial Tower 2, Block B, Greenwood City, Unit 1-3, Sector 45, Gurugram, Haryana 122003
Write to us : support@univest.in, compliance@univest.in
Verify on SEBI registry →RESEARCH ANALYST
Get SEBI Registered
advice on the stocks
trending today.
Get 3 FREE Trade Ideas
for Startups Accelerator 2024
Trusted by 1Cr Indians
Awarded No.1 by Economic Times





